Domain Therapeutics SA of Strasbourg, France has appointed Xavier Leroy to the position of chief technology officer (CTO) to drive development of the company’s G protein-coupled receptor (GPCR) drug discovery platform. GPCRs are a family of membrane receptors that are the target of many potential therapies. Dr Leroy joins Domain from iTeos Therapeutics SA in Belgium where he was head of drug discovery. Before that, he spent more than 13 years at Actelion Pharmaceuticals AG (now part of Johnson & Johnson Inc) where he developed multiple GPCR programmes in the fields of neuroscience and inflammation.
Dr Leroy obtained a PhD in molecular and cellular biology from the Université de Bretagne Occidentale, France in 2000.
Domain Therapeutics announced the appointment on 8 July 2019.
Copyright 2019 Evernow Publishing Ltd